Eric Bluestein joined Newmark in 2021 and currently serves as an Executive Managing Director. Eric brings over 20 years of expertise in sales and leadership positions, and specializes in representing tenants and landlords in the life sciences and technology sectors. Eric collaborates with his clients to develop and execute creative real estate strategies, with a focus on meeting both short and long-term objectives.
Eric’s diverse client roster includes Arsenal Biosciences, Ascendis Pharma, Bayer Healthcare, Neuralink, Bristol Myers Squibb, Codexis, Exelixis, RAPT Therapeutics, 23&Me, Veracyte, Madison Reed, NIO, Alexandria, Wareham Development, SKS Investments. At Newmark, Eric will align with its Capital Markets Northern California team to augment the firm’s full-scale advisory services within the life science and tech sectors.
Prior to Newmark, Eric was an Executive Vice President and Shareholder at Kidder Matthews and a Top 5 Producer from 2015 to 2020.